TOP TIERMARKET NEWSWIRE

News & sentiment

ERASCA INC (ERAS) — News & AI sentiment

ERASCA INC (ERAS) news roundup. 6 stories in the past week, 20 over 30 days. Average 30-day sentiment is 59/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

6

avg sentiment 54/100

30d stories

20

avg sentiment 59/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

ERAS news in the last 24 hours, 7 days, 30 days and 90 days

How much ERAS coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	ERAS stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	6	54/100	ERAS headlines →
Last 30 days	20	59/100	ERAS headlines →
Last 90 days	124	45.2/100	ERAS headlines →

Latest stories on ERAS

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf

GlobeNewswire50 · neutralgeneral

3d ago

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

StockTitan56 · neutralproduct/pr

3d ago

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

GlobeNewswire56 · neutralproduct/pr

3d ago

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your Behalf

GlobeNewswire50 · neutralgeneral

5d ago

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire56 · neutralgeneral

5d ago

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Business Insider56 · neutralgeneral

5d ago

FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage

Yahoo Finance73 · bullishproduct/pr

Sep 4

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); Hyliion Holdings Corp. (NYSE: HYLN); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your Behalf

GlobeNewswire50 · neutralgeneral

Sep 3

ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

GlobeNewswire50 · neutralgeneral

Sep 2

Erasca price target raised to $33 from $25 at JPMorgan

The Fly64 · neutralanalyst

Aug 27

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); New Era Energy & Digital, Inc. (NASDAQ: NUAI) (formerly known as New Era Helium (NASDAQ: NEHC)); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf

GlobeNewswire50 · neutralgeneral

Aug 26

Erasca Receives FDA Fast Track for ERAS-0015 in Pancreatic Cancer: Phase 1 Data Shows 57% Response Rate August 24, 2026

MarketChameleon73 · bullishproduct/pr

Aug 24

Erasca Wins FDA Fast Track for Pancreatic Therapy

TipRanks73 · bullishproduct/pr

Aug 24

Erasca, Inc. (ERAS) files 8-K

SEC 8-K50 · neutralgeneral

Aug 24

Erasca granted Fast Track Designation for ERAS-0015

The Fly67 · bullishproduct/pr

Aug 24

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

StockTitan73 · bullishproduct/pr

Aug 24

Stifel reiterates Buy rating on Erasca stock, $30 target

Investing.com Analyst Ratings61 · neutralanalyst

Aug 17

Erasca price target raised to $21 from $20 at Guggenheim

The Fly61 · neutralanalyst

Aug 17

Erasca price target raised to $20 from $18 at BofA

The Fly61 · neutralanalyst

Aug 16

Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf

GlobeNewswire50 · neutralgeneral

Aug 14

Guggenheim raises Erasca stock price target to $21 on pipeline progress

Investing.com Analyst Ratings61 · neutralanalyst

Aug 13

H.C. Wainwright raises Erasca stock price target on trial progress

Investing.com Analyst Ratings61 · neutralanalyst

Aug 12

Erasca reports Q2 EPS (14c), consensus (11c)

The Fly56 · neutralearnings

Aug 11

Erasca, Inc. (ERAS) files 8-K

SEC 8-K50 · neutralgeneral

Aug 11

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

StockTitan34 · bearishearnings

Aug 11

Open ERAS in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →